Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amphiron Deep is a specialized topical lipid-based formulation of amphotericin B, a polyene antifungal and antiprotozoal agent. Developed by Bharat Serums and Vaccines, it is primarily indicated for the treatment of cutaneous leishmaniasis, a parasitic disease caused by *Leishmania* species. The "Deep" formulation is engineered to enhance the transdermal penetration of the large amphotericin B molecule, allowing it to reach the deeper layers of the dermis where the parasites reside within macrophages. Mechanistically, amphotericin B binds to ergosterol in the cell membranes of fungi and *Leishmania* promastigotes and amastigotes, leading to the formation of aqueous pores. These pores cause the leakage of essential intracellular ions, such as potassium, resulting in cell lysis and death. This topical delivery system aims to provide high local drug concentrations while significantly reducing the risk of nephrotoxicity and other systemic side effects associated with parenteral amphotericin B administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amphiron Deep.